Life Tech Capital Reports On NovaBay's NeutroPhase

According to Life Tech Capital, NovaBay Pharmaceuticals NBY presented a poster on the efficacy of NeutroPhase (NVC-101) solution with Pioneer Technology's (private) hydrophobic mesh Sorbact in healing chronic non-healing wounds at the 2011 Symposium on Advanced Wound Care (SAWC) in Dallas on April 15-16. Life Tech Capital reported that the poster titled "NeutroPhase with Sorbact Dramatically Enhances the Speed of Wound Healing" reported on multiple case studies in the clinic in which a combination of 0.01% NeutroPhase with Sorbact as a wound mesh dressing in conjunction with Negative Pressure Wound Therapy (NPWT) administered to 26 patients with chronic non-healing wounds. “NeutroPhase is an FDA-cleared solution containing HOCI (hypochlorous acid) which is rapid-acting but short-lived making it ideal for multiple applications, especially in surface wound care. NeutroPhase is expected to begin FDA validated large-scale manufacturing during 2011 and available for sale in 2012 through NovaBay's Hospital Business unit for patients suffering from chronic non-healing wounds such as diabetic, pressure, and venous stasis ulcers.” NovaBay Pharmaceuticals closed yesterday at $2.32.